Hypomagnesemic and hypocalcemic coma, convulsion and eye movement disorders after chemotherapy with platinum compounds;COMA, CRISE CONVULSIVE ET TROUBLES DE L'OCULOMOTRICITE HYPOMAGNESEMIQUES ET HYPOCALCEMIQUES APRES CHIMIOTHERAPIE PAR SELS DE PLATINE

Revue de Medecine Interne

Volumn 17, Issue 6, 1996, Pages 467-469

  Bachmeyer, C ^a   Decroix, Y ^a   Medioni J ^a   Dhote R ^a   Benfiguig, K ^a   Houillier, P ^b   Grateau, G ^a  

^a HÔTEL DIEU   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

cisplatin; hypocalcemia; hypomagnesemia; neurological manifestations

Indexed keywords

CALCIUM; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; MAGNESIUM; MITOXANTRONE; PIRARUBICIN;

ADULT; ARTICLE; CASE REPORT; CHEMOTHERAPY; COMA; CONVULSION; FEMALE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; KIDNEY TUBULE DAMAGE; OVARY ADENOCARCINOMA;

EID: 0029904279     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/0248-8663(96)86439-3     Document Type: Article

References (17)

1. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 1989;25:1-9
2. Ettinger LJ, Gaynon PS, Krailo MD et al. A Phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the children's cancer group. Cancer 1994;73:1297-301
3. Bitran JD, Desser RK, Billings AA, Kozloff, Shapiro CM. Acute nephrotoxicity following cis-dichlorodiamine-platinum. Cancer 1982;49:1784-8
4. Buckley JE, Clark UL, Meyer T, Pearlman NW. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 1984;144:2347-8
5. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 1982;66:1767-9
6. Gonzales C, Villasanta U. Life-threatening hypocalcemia and hypomagnesemia associated with cisplatin chemotherapy. Obstet Gynecol 1982;59:732-4
7. Chauffert B, Chevet D, Chantereau MJ, Tanter Y, Charffedine K, Lorcerie B. Hypocalcémie induite par le cisplatine. Réponse parathyroïdienne inappropriée due à l'hypomagnésémie. Presse Méd 1991;20:1288-9
8. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985;12 (suppl A):125-36
9. Beuzeboc P, Deygere H, Boccaccio F, Christoforov B. Coma hypomagnésémique hypocalcémique après carboplatine. Presse Méd 1989;18:1343-4
10. Phelps JS, Gandolfi AJ, Brendel K, Dorr RT. Cisplatin nephrotoxicity: in vitro studies with precision cut-rabbit renal cortical slices. Toxicol Appl Pharmacol 1987;90:501-12
11. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 1988;44:164-72
12. Sartori S, Nielsen I, Tassinari D, Rigolin F, Arcudi D, Abbasciano V. Changes in intracellular magnesium concentrations during cisplatin chemotherapy. Oncology 1993;50:230-4
13. Daugaard G, Abildgaard U, Holstein-Rathlou N-H, Leyssac PP, Amtorp O, Dikhoff TG. Acute effects of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol 1986;9:308-16
14. Stewart AF, Keating T, Schwartz PE. Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol 1985;153:660-5
15. Hayes FA, Green AR, Casper J, Cornet J, Evans WE. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. Cancer 1981;48:1715-8
16. Suh SM, Tashjian AH, Matsuo N, Parkinson DK, Fraser D. Pathogenesis of hypocalcemia in primary hypomagnesemia: normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function. J Clin Invest 1973;52:153-60
17. Martin M, Diaz-Rubio E, Casado A, Lopez Vega JM, Sastre J, Almenarez J. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 1992;15:348-51